维持癌症患者的运动能力，从而维持患者自主生活能力具有重要性，但关于其主要影响因素了解甚少。我们旨在确定各种类型癌症患者运动能力的影响因素，这些患者已经接受了癌症治疗或即将开始此类治疗。通过运用6分钟步行测试（6-MWT），对253例连续患者进行了运动能力评估，这些患者多数患有晚期癌症。所有患者均接受了超声心动图检查、体格检查、静息心电图、手握力（HGS）测量以及实验室评估。根据6-MWT中值距离（459 m）将患者分为两组。较低运动能力的患者年龄较大，HGS和血红蛋白水平明显较低，高敏感（hs）肌钙蛋白T和NT-proBNP水平较高（均p < 0.05）。尽管这一组患者的合并症负担显著增加，但性别、体重指数、肿瘤类型或消瘦等方面未发现差异（均p > 0.2）。通过多元逻辑回归分析，我们发现贫血存在（奥斯比比（OR）为6.172，95%置信区间（CI）为1.401-27.201，p = 0.016）以及hs肌钙蛋白T增加（OR为3.077，95%CI为1.202-5.301，p = 0.019）仍然是预测运动能力受损的独立因素。HGS增加与运动能力降低风险减少相关（OR为0.896，95%CI为0.813-0.987，p = 0.026）。筛查具有高hs肌钙蛋白水平和降低HGS的患者可能有助于识别癌症治疗期间运动能力降低的风险患者。© 2023. Springer Nature Limited.

Maintaining cancer patients' exercise capacity and therefore patients' ability to live a self-determined life is of huge importance, but little is known about major determinants. We sought to identify determinants of exercise capacity in patients with a broad spectrum of cancer types, who were already receiving cancer treatment or about to commence such therapy. Exercise capacity was assessed in 253 consecutive patients mostly suffering from advanced cancer using the 6-min walk test (6-MWT). All patients underwent echocardiography, physical examination, resting electrocardiogram, hand grip strength (HGS) measurement, and laboratory assessments. Patients were divided into two groups according to the median distance in the 6-MWT (459 m). Patients with lower exercise capacity were older, had significantly lower HGS and haemoglobin and higher values of high sensitive (hs) Troponin T and NT-proBNP (all p < 0.05). Whilst the co-morbidity burden was significantly higher in this group, no differences were detected for sex, body mass index, tumor type, or cachexia (all p > 0.2). Using multivariable logistic regression, we found that the presence of anaemia (odds ratio (OR) 6.172, 95% confidence interval (CI) 1.401-27.201, p = 0.016) as well as an increase in hs Troponin T (OR 3.077, 95% CI 1.202-5.301, p = 0.019) remained independent predictors of impaired exercise capacity. Increasing HGS was associated with a reduced risk of a lower exercise capacity (OR 0.896, 95% CI 0.813-0.987, p = 0.026). Screening patients for elevated hs troponin levels as well as reduced HGS may help to identify patients at risk of lower exercise capacity during cancer treatment.© 2023. Springer Nature Limited.